Pregled bibliografske jedinice broj: 267399
Evaluation of DNA damage induced by atrazine and atrazine-based herbicide in human lymphocytes in vitro using a comet and DNA diVusion assay
Evaluation of DNA damage induced by atrazine and atrazine-based herbicide in human lymphocytes in vitro using a comet and DNA diVusion assay // Toxicology in Vitro, 20 (2006) (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 267399 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Evaluation of DNA damage induced by atrazine and atrazine-based herbicide in human lymphocytes in vitro using a comet and DNA diVusion assay
Autori
Želježić, Davor ; Garaj-Vrhovac, Vera ; Perković, Petra
Izvornik
Toxicology in Vitro (0887-2333) 20
(2006);
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Atrazine; Genotoxicity; Apoptosis; Human lymphocytes; Comet assay; DNA diVusion assay; Metabolic activation
Sažetak
Atrazine is one of the most widely used herbicides in the world. When applied, it is not used as a pure active ingredient but in the form of commercial formulations. Besides atrazine, these formulations contain other substances that might represent a risk to human health due to their mutual interactions. We evaluated the genotoxicity, apoptosis and necrosis induction of atrazine as an active ingredient, the commercial formulation Gesaprim® , and a Gesaprim® adjuvant mixture without atrazine by comet and DNA diVusion assay, respectively. Human lymphocytes were treated for 0.5, 1, 3, 5, and 8 h with 0.047 g/ml, 0.47 g/ml, 4.7 g/ml of substances tested both in the presence and in the absence of an exogenous metabolic activator. Atrazine did not appear to be genotoxic or to be capable of inducing apoptosis or necrosis. Unlike atrazine, Gesaprime® and the adjuvant mixture increased DNA damage in lymphocytes. After 5 h of treatment, it also increased the number of apoptotic cells. Metabolic activation additionally enhanced the DNA-damaging potential of Gesaprim ® and the adjuvant mixture but did not aVect atrazine genotoxicity. Thus, both assay endpoints diVered signiWcantly for the active ingredient and formulation. To evaluate the potential health risk of simultaneous exposure to adjuvants and an active ingredient, further eVorts using a biomonitoring approach should be made.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
POVEZANOST RADA
Projekti:
0022020
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- Index Medicus